Navigation Links
Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
Date:12/17/2009

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

The new Special European Physician & Payer Forum report entitled Targeted Therapies for NSCLC: How High are the Barriers to Displacing Avastin in Europe? finds that Avastin, which is not recommended for use within the United Kingdom's National Health Service, is used more often for non-small-cell lung cancer in the first and second line in France and Germany than in Italy and Spain. However, over the next 12 months, surveyed oncologists in Italy and Spain expect to increase first-line use of targeted agents such as Avastin, OSI Pharmaceuticals/Roche/Chugai's Tarceva and AstraZeneca's Iressa. According to the report, Tarceva is the second-most commonly prescribed targeted therapy in the first line after Avastin.

While Avastin, Tarceva and Iressa have shown modest efficacy in select patient populations, other agents in late-stage development have struggled to reach the non-small-cell lung cancer drug market. Three targeted therapies -- Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux, AstraZeneca's Zactima and Pfizer's figitumumab -- experienced recent setbacks in ongoing Phase III clinical trials or in receiving approval from the European Medicines Agency.

"The landscape for non-small-cell lung cancer will shift over the next several years as oncologists and payers grapple with the role of maintenance/consolidation therapy, increasing uptake of targeted therapies in the first-line setting and with the potential launch of new biologic agents," said Decision Resources Director Madhuri Borde, Ph.D.

The report also finds that cost-sharing schemes for targeted therapies -- which have been negotiated by the Italian Medicines Agency for both Avastin and Tarceva -- are much more prevalent in Italy than in the other European countries surveyed. Negotiating cost-sharing schemes is one of several factors that can contribute to delayed uptake of targeted therapies in Italy. Other factors include the time the agency spends reviewing new drug applications, setting prices and the requirement that new drugs must be accepted onto both regional and hospital formularies prior to their use.

Targeted Therapies for NSCLC: How High are the Barriers to Displacing Avastin in Europe? is based on surveys with 224 oncologists and interviews with 20 hospital-based payers in Germany, France, Italy, Spain and the United Kingdom. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563
    ccomfort@dresources.com                   emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
2. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
5. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
6. European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient
7. A Drugs Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections
8. Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8
9. Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
10. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
11. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... "Global Markets for Emerging Medical Device Technologies" report to ... ... heart valves, open procedures, general instruments, non-drug coated implantables, large ... have been in use over the last two to three ...
(Date:2/16/2017)... The Lockwood Group (Lockwood), a medical communications agency, ... in Connecticut list by the ... a row that Lockwood has been in the top 10, ... spot in 2017. The award recognizes companies that have been ... determined through a survey conducted by The Best Companies Group ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications provided ... visit are necessary for long-term opioid use to take ... 16 th edition of The New England ... physicians see more patients in acute pain than in ... , MD, FACEP, president of the American College of ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... services, announced today that Karen Pilley has been promoted to Chief Executive Officer. ... today’s shifting healthcare paradigm – a shift that demands the transition from pay-for-service ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics ... Medicine Tri-Conference February 20 – 22 in San Francisco. As part of the ... and molecular pathology workflow solution, as well as its new precision medicine platform, ...
(Date:2/17/2017)... Williamsburg, VA (PRWEB) , ... February 17, 2017 ... ... asset protection services and financial planning assistance to families and business owners in ... Center for a charity drive to help prevent all forms of domestic violence. ...
(Date:2/16/2017)... ... February 17, 2017 , ... For ... long after their final treatments. Physician researchers at The Marcus Institute of ... mind-body therapy, for efficacy in reducing symptoms of traumatic stress in cancer patients ...
(Date:2/16/2017)... , ... February 16, 2017 , ... ... professionalism, teamwork and superiority in patient care, NWH has achieved Magnet® recognition ... Magnet on Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet Recognition ...
Breaking Medicine News(10 mins):